

Janssen Announces Agreements to Expand Research and Development Efforts in Russia

New licensing agreements in oncology* and tuberculosis** announced at the Gaidar Forum

Moscow, January 18 2013 – **Janssen Pharmaceutica NV (Janssen)** announced today during the Gaidar Forum, an annual economic and political gathering, the signing of two licensing agreements for drug development and commercialization in the areas of oncology and tuberculosis with NewVac LLC, a ChemRar company, and Pharmstandard JSC, respectively. These partnerships support the research and development program for Janssen in Russia.

“The agreements with Pharmstandard JSC and NewVac build on partnerships started in 2011 and 2012, and continue our strategy of cooperation in research and development and open transfer of knowledge and technology to our Russian partners,” said Dr. Paul Stoffels, Company Group Chairman, Global Research & Development, Pharmaceuticals at Johnson & Johnson. “We believe that a long-term cooperation with Russian manufacturers and authorities can help provide patients with the best treatment options for a number of underserved disease areas.”

Under the terms of the agreement with NewVac, Janssen granted co-exclusive rights to the company in Russia and Commonwealth of Independent States (CIS) for the development and commercialization of the Histone Deacetylase Inhibitor (HDACi) program for the treatment of solid tumors treatment.

Janssen retains the rights for the development and commercialization of HDACi for hematologic malignancies worldwide. NewVac will develop Janssen product quisionstat, including clinical trial and development in the Russian Federation. Janssen will provide its expertise in development and conducting external global clinical trials.

Through the agreement with Pharmstandard JSC, Janssen grants rights to its compound bedaquiline in Russia and CIS for the treatment of pulmonary multi-drug resistant tuberculosis (MDR-TB) in adults. If approved in Russia, bedaquiline would be the first TB drug with a new mechanism of action in nearly 40 years. Pharmstandard will be responsible for the production and commercialization of bedaquiline in Russia and CIS, including product registration with regulatory authorities and coordination with national authorities to ensure responsible and appropriate product availability. Janssen and Pharmstandard will set up a Joint Steering committee to discuss regulatory, supply, medical and/or scientific issues relating to bedaquiline. The Committee will also agree on an appropriate strategy to ensure appropriate use of

bedaquiline, in order to limit the risk for avoidable resistance to the compound. Janssen will transfer product Know How, technology and expertise to conduct local manufacturing in line with the Pharma 2020 strategy in Russia.

Based on the Pharma 2020's key priority for accelerating development of innovative pharmaceutical industry announced by the Russian government, Janssen transfers the knowledge and expertise in all or several stages of R&D cycle "from molecule to medicine" for certain of its products to partners in Russia. In 2011 and 2012 Janssen signed two agreements with Russian companies: a co-investment agreement with ChemRar and Skolkovo; and a discovery collaboration agreement with ChemDiv.

Contacts for media:

Maria Vikhlyaeva (+7 916 115 71 63, mvikhlya@its.jnj.com)

Svetlana Voronina (+7 910 457 79 70, svetlana.voronina@ketchum.com)

References:

*Oncology is the second fatality cause in Russia (http://www.gks.ru/bgd/regl/b11_13/IssWWW.exe/Stg/d6/26-06.htm). In 2011 522,410 new cases of cancer were detected in Russian Federation. It's a 1.1% increase compared to 2010.

**Tuberculosis (TB) incidence rate in Russia started to grow since 1991. Federal Service on Surveillance for Consumer Rights Protection and Human Well-Being (Rosпотребнадзор) states that nearly 117-120 thousand of new TB cases appear every year. 10% of the new cases relate to multidrug-resistant tuberculosis (MDR-TB). 240 237 people were infected with TB and put under medical observation in 2011 (compared to 253 555 in 2010).

About Janssen Pharmaceutica NV

Janssen Pharmaceutica NV is a part of Janssen pharmaceutical companies of Johnson & Johnson.

The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology, immunology, neuroscience, infectious disease, and cardiovascular and metabolic diseases.

Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.

Janssen is one of the top ten pharmaceutical companies in the Russian market, making significant contributions to the health care system, increasing the availability of new drugs and helping Russians live longer and better.

###

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Products, LP and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; manufacturing difficulties or delays; and product efficacy or safety concerns. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Janssen Products, LP nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments).